Abstract
“Blood banking has become a manufacturing industry, an industry that must conform to high standards and quality control requirements comparable to those of pharmaceutical companies or other regulated industries,” said David A. Kessler, M.D., former FDA commissioner (Revelle, 1995). Screening donated blood for infectious diseases that can be transmitted through blood transfusion is very important in ensuring safety. The United States has the safest blood supply in the world (Revelle, 1995), and the Food and Drug Administration (FDA) is striving to keep it safe by decreasing the risk of infectious disease transmission. The regulatory agency is continuously updating its requirements and standards for collecting and processing blood. An important step in ensuring safety is the screening of donated blood for infectious diseases. In the United States, tests for infectious diseases are routinely conducted on each unit of donated blood, and these tests are designed to comply with regulatory requirements (Table 21.1). The field of clinical microbiology and virology is now moving into the focus of molecular technology. Currently, nucleic acid testing techniques have been developed to screen blood and plasma products for evidence of very recent viral infections that could be missed by conventional serologic tests. It is time for all blood safety staffs to use molecular detection techniques. This approach can significantly aid in blood safety to reduce the risk of transmission of serious disease by transfusion. This chapter will review the current antigen/antibody–based technology, molecular biological technology, and published regulatory policy data for blood safety.
Chapter PDF
Similar content being viewed by others
Keywords
- West Nile Virus
- Severe Acute Respiratory Syndrome
- Severe Acute Respiratory Syndrome
- Window Period
- Nucleic Acid Testing
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Biggerstaff, B.J., & Peterson, L.R. (2003). Estimated risk of transmission of the West Nile Virus through blood transfusion in the US, 2002. Transfusion, 43,1007–1017.
Blut, A. (2000). TT Virus. Infusion Therapy Transfusion Medicine, 27, 114–116.
CDC. (1997). Immunization of health-care workers: Recommendations of the advisory committee on immunization practices (ACIP) and the hospital infection control practices advisory committee (HICPAC). Morbid Mortal Weekly Rep, 46, 1–42.
Chamberland, M.E. (2001). Emerging infectious disease issues in blood safety. Emer Infect Dis, 7, 552–553.
Cohen J. (1999). The scientific challenge of hepatitis C. Science, 285, 26–30.
Cossart, Y. (2000). TTV-a virus searching for a disease. J Clini Virol, 17, 1–3.
Das, K., Kar, P., Gupta, R., & Das, B. (2004). Role of transfusion-transmitted virus in acute viral hepatitis and fulminant hepatic failure of unknown etiology. J Gastroenterol Hepato, 19,406–412.
Ginocchio, C.C., Kemper, M., Stellrecht, K.A., & Witt, D.J. (2003). Multicenter evaluation of the performance characteristics of the nucliSens HIV-1 QT assay used for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol, 41, 164–173.
Green, P.L., & Chen, I.S.Y. (2001). Human T-cell leukemia virus types 1 and 2. Section two: specific virus families, Fields Virology, Fourth ed. Lippincott Williams & Wilkins, Philadelphia, 1, (pp. 1941–1969).
Guichon, A., Chiparelli, H., Martinez, A., Rodriguez, C.,Trento, A., Russi, J.C., & Carballal, G. (2004). Evaluation of a new NASBA assay for the qualitative detection of hepatitis C virus based on the NucliSens Basic Kit reagents. J Clin Virol, 29,84–91.
Hersing, D.H. (1993). In vitro nucleic acid amplification techniques. In Diagnostic Molecular Microbiology Principles and Applications. Mayo Foundation, Rochester, MN, ASM Press, pp. 51–87.
Hu, Y., and Hirshfield, I. (2005). Rapid approach to identify an unrecognized viral agent. J Virol Methods, 127, 80–86.
Hu,Y., Shahidi, A., Park, S., Guilfoyle, D., & Hirshfield, I. (2003). Detection of extrahepatic HCV replication by a novel highly sensitive single tube nested-PCR. Am J Clin Pathol, 119, 95–100.
Hollinger, F.B., & Jake, T. (2001). Hepatitis B virus. Section two: specific virus families. Fields Virology. Fourth ed. LippincottWilliams Wilkins. & Philadelphia, 87, (pp. 2971–3036.)
Katsoulidou, A.S., Moschidis, Z.M., Gialeraki, R.E., Paraskevis, D.N., Sypsa, V.A., Lazanas, M.C., Tassopoulos, N.C., Psichogiou, M.A., Boletis, J.N., Karafoulidou, A.S., & Hatzakis, A.E. (2004). Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion. Transfusion, 44, 59–66.
Krajden, M., Comanor, L., Rifkin, O., Grigoriew, A., Minor, J.M., & Kapke, G.F. (1998). Assessment of hepatitis B virus DNA stability in serum by the Chiron quantiplex branched- DNA assay. J Clin Microbiol, 36, 382–386.
Lamballerie, XD. (1996). Serological and molecular biology screening techniques for HCV infection. Nephrol Dialysis Transplant, 4, 9–11. Abbott Laboratories. 2003. LCx HIV RNA quantitative assay from Abbott Laboratories. Abbott Laboratories, Abbott Park, IL.
Major, M.E., Rehermann, B., & Feinstone, S.M. (2001). Hepatitis C viruses. Section two: specific virus families. Fields Virology, Fourth ed. Lippincott Williams & Wilkins, Philadelphia, (pp.1127–1161).
Mornet, E. (2004). DNA, 50 years of the double helix: from the concept of molecular hybridization to microarrays. Gynecol Obstetr Fertil, 3,895–899.
Nishizawa, T., Okamoto, H., Konishi, K., Yoshizawa, H., Miyakawa, Y., & Mayumi, M. (1997). A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun, 241,92–97.
Okamoto, H. Nishizawa, T., & Ukita, M. (1999). A novel unenveloped DNA virus (TT virus) associated with acute and chronic non-A to G hepatitis. Intervirology, 42, 192–204.
Palmer, S., Wiegand, A.P., Maldarelli, F., Bazmi, H., Mican, J.M., Polis, M., Dewar, R.L., Planta, A., Liu, S., Metcalf, J.A., Mellors, J. W., & Coffin, J.M. (2003). New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol, 41, 4531–4536.
Pass, R.F. (2001). Cytomegalovirus. Section two: specific virus families. Fields Virology, Fourth ed. Lippincott Williams & Wilkins, Philadelphia, (pp. 2676–2705).
Hayden, R.T. (2004). In vitro nucleic acid amplification techniques. In: Persing, D.H., Tenover, F.C., Versalovic, J., Tang, Y. W., Unger, E.R., Relman, D.A., & White, T.J., eds., Molecular Microbiology: Diagnostic Principles and Practice. Washington, DC, ASM Press, pp. 43–69.
Peter, J.B., & Sevall, J.S. (2004). Molecular-based methods for quantifying HIV viral load. AIDS Patient Care STDS, 18, 75–79.
Revelle, M. (1995). Progress in blood supply safety. FDA Consumer Magazine, 29, 21–24.
Roche. 2003. Roche Amplicor HIV-1 Monitor UltraSensitive quantitative assay. Roche, Nutley, New Jersey.
Schena, M. (2002). Introduction to microarray analysis. In Microarray Analysis. JohnWiley & Sons, Hoboken, NJ, pp. 1–26.
Starkey, W.G., Millar, R.M., Jenkins, M.E., Ireland, J.H., Muir, K.F., & Richards, R.H. (2004). Detection of piscine nodaviruses by real-time nucleic acid sequence based amplification (NASBA). Dis Aquatic Organisms, 5,93–100.
Stramer, S.L., Glynn, S.A., Kleinman, S.H., Strong, D.M., Sally, C., Wright, D.J., Dodd R.Y., & Busch, M.P. 2004. Detection of HIV-1 and HCV infections among antibodynegative blood donors by nucleic acid-amplification testing. N Engl J Med, 19, 819–822.
Tang, Y. W., Procop, G. W., & Persing, D.H. (1997). Molecular diagnostics of infectious diseases. Clin Chem, 43, 2021–2038.
U.S. Food& Drug Administration. (2004). Testing requirements for communicable disease agents. Federal Register, 21CFR 610:40, 75–80.
Wang, Q.M., & Heinz, B.A. (2001). Recent advances in prevention and treatment of hepatitis C virus infections. Progress Drug Res, Spec, 79–110.
Yu, X., Susa, M., Knabbe, C., Schmid, R.D., & Bachmann, T.T. (2004). Development and validation of a diagnostic DNA microarray to detect quinoloneresistant Escherichia coli among clinical isolates. J Clin Microbiol, 42, 4083–4091.
Rights and permissions
Copyright information
© 2006 Springer
About this chapter
Cite this chapter
Hu, Y., Hirshfield, I. (2006). Molecular Techniques for Blood and Blood Product Screening. In: Advanced Techniques in Diagnostic Microbiology. Springer, Boston, MA. https://doi.org/10.1007/0-387-32892-0_21
Download citation
DOI: https://doi.org/10.1007/0-387-32892-0_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29741-5
Online ISBN: 978-0-387-32892-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)